259 related articles for article (PubMed ID: 28316003)
1. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
[TBL] [Abstract][Full Text] [Related]
2. Gammaplex
Wasserman RL
Immunotherapy; 2017 Oct; 9(13):1071-1088. PubMed ID: 29032734
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases.
Melamed IR; Gupta S; Stratford Bobbitt M; Hyland N; Moy JN
Clin Exp Immunol; 2016 May; 184(2):228-36. PubMed ID: 26696596
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
[TBL] [Abstract][Full Text] [Related]
5. A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID).
Viallard JF; Brion JP; Malphettes M; Durieu I; Gardembas M; Schleinitz N; Hoarau C; Lazaro E; Puget S
Rev Med Interne; 2017 Sep; 38(9):578-584. PubMed ID: 28683953
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.
Heimall J; Chen J; Church JA; Griffin R; Melamed I; Kleiner GI
J Clin Immunol; 2016 Aug; 36(6):600-9. PubMed ID: 27342758
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of Gammaplex® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075).
Dash CH; Gillanders KR; Stratford Bobbitt ME; Gascoigne EW; Leach SJ
PLoS One; 2014; 9(6):e96600. PubMed ID: 24892422
[TBL] [Abstract][Full Text] [Related]
8. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
[TBL] [Abstract][Full Text] [Related]
9. An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease.
Kriván G; Königs Ch; Bernatowska E; Salama A; Wartenberg-Demand A; Sonnenburg C; Linde R
Vox Sang; 2015 Oct; 109(3):248-56. PubMed ID: 25953213
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
[TBL] [Abstract][Full Text] [Related]
11. Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.
Ballow M; Pinciaro PJ; Craig T; Kleiner G; Moy J; Ochs HD; Sleasman J; Smits W
J Clin Immunol; 2016 Aug; 36(6):583-9. PubMed ID: 27279130
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
[TBL] [Abstract][Full Text] [Related]
13. BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children.
Kriván G; Borte M; Soler-Palacin P; Church JA; Csurke I; Harris JB; Lieberman JA; Melamed IR; Moy JN; Simon R; Aigner S; Lentze S; Staiger C
J Clin Immunol; 2023 Apr; 43(3):557-567. PubMed ID: 36383294
[TBL] [Abstract][Full Text] [Related]
14. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
Kobayashi RH; Gupta S; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Turpel-Kantor E; Litzman J
Front Immunol; 2019; 10():40. PubMed ID: 30778345
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.
Moy JN; Scharenberg AM; Stein MR; Suez D; Roberts RL; Levy RJ; Ballow M; Fasano MB; Dash CH; Leach SJ
Clin Exp Immunol; 2010 Dec; 162(3):510-5. PubMed ID: 21070209
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
Debes A; Bauer M; Kremer S
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease.
Kriván G; Borte M; Harris JB; Lumry WR; Aigner S; Lentze S; Staiger C
Vox Sang; 2022 Oct; 117(10):1153-1162. PubMed ID: 35944615
[TBL] [Abstract][Full Text] [Related]
19. A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.
Kreuz W; Erdös M; Rossi P; Bernatowska E; Espanol T; Maródi L
Clin Exp Immunol; 2010 Sep; 161(3):512-7. PubMed ID: 20550545
[TBL] [Abstract][Full Text] [Related]
20. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]